Aileron Therapeutics (ALRN) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free ALRN Stock Alerts $5.06 +0.13 (+2.64%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAileron Therapeutics (NASDAQ:ALRN) PT Raised to $19.00 at LADENBURG THALM/SH SHamericanbankingnews.com - April 20 at 2:46 AMmarketbeat.com - April 18 at 9:35 AMALRN Stock Earnings: Aileron Therapeutics Reported Results for Q4 2023investorplace.com - April 16 at 11:05 AMAileron Therapeutics, Inc.: Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatefinanznachrichten.de - April 16 at 7:37 AMAileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Updateamericanbankingnews.com - April 16 at 5:52 AMAileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - April 15 at 5:20 PMAileron Therapeutics CEO Manuel Aivado Steps Down; Names Brian Windsor Replacementmarkets.businessinsider.com - March 12 at 1:36 PMAileron Therapeutics Announces CEO Transitionglobenewswire.com - March 12 at 8:00 AMmarketbeat.com - February 28 at 9:37 AMAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Eventfinance.yahoo.com - February 15 at 8:58 PMAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Eventglobenewswire.com - February 15 at 4:05 PMAileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024finance.yahoo.com - February 1 at 8:17 PMAileron Therapeutics Announces Director Nomination Detailsmsn.com - January 30 at 10:33 AMAileron Therapeutics Announces 2024 Annual Meeting Plansmsn.com - January 30 at 10:33 AMmarketbeat.com - January 30 at 9:49 AMAileron Therapeutics Stock (NASDAQ:ALRN) Dividends: History, Yield and Datesbenzinga.com - December 27 at 10:42 PMU.S. shares higher at close of trade; Dow Jones Industrial Average up 0.43%msn.com - December 15 at 7:38 AMAileron Therapeutics upgraded to Buy from Neutral at Ladenburgrealmoney.thestreet.com - December 1 at 3:46 PMAileron Therapeutics upgraded to Buy at Ladenburg after Lung Therapeutics dealrealmoney.thestreet.com - December 1 at 3:46 PMAileron Therapeutics Director Awarded $6K Worth of Stock Optionsbenzinga.com - November 5 at 3:03 PMAileron gains after all-stock deal to acquire Lung Therapeuticsmsn.com - November 1 at 3:15 PMAileron Therapeutics Announces Acquisition of Lung Therapeuticsfinance.yahoo.com - October 31 at 5:03 PMBears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Nowfinance.yahoo.com - April 4 at 1:28 PMAileron Therapeutics, Inc. (ALRN)finance.yahoo.com - March 22 at 8:03 AMAileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowfinance.yahoo.com - March 14 at 6:11 PMLooking Into Aileron Therapeutics's Recent Short Interestmsn.com - March 3 at 6:51 PMJonesTrading Keeps Their Hold Rating on Aileron Therapeutics (ALRN)markets.businessinsider.com - February 23 at 8:54 AMCancer drugmaker down to 3 employees after trial failurefinance.yahoo.com - February 22 at 5:26 PMU.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.06%msn.com - February 21 at 5:59 PMAileron off 38% on plans to explore sale after setback for cancer candidateseekingalpha.com - February 21 at 5:59 PMAileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fallfinance.yahoo.com - February 21 at 5:59 PMAileron Terminates Phase 1b Breast Cancer Chemoprotection Trial Of ALRN-6924markets.businessinsider.com - February 21 at 12:59 PMAileron Therapeutics Shares Slide to New Low on Lead Drug Failure >ALRNmarketwatch.com - February 21 at 12:59 PMAileron Exploring Options After ALRN-6924 Study Failure >ALRNmarketwatch.com - February 21 at 12:59 PMmarketbeat.com - February 21 at 8:29 AMalrn.a - | Stock Price & Latest News | Reutersreuters.com - January 17 at 1:37 PMWhat Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stockmsn.com - December 29 at 1:22 PMAileron Therapeutics Regains Compliance with Nasdaq Listing Requirementsfinance.yahoo.com - November 30 at 8:00 AMAileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Nowfinance.yahoo.com - November 24 at 1:38 PMAileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Increase in Short Interestmarketbeat.com - November 13 at 5:10 AMAileron Therapeutics, Inc.: Aileron Therapeutics Announces a 1-for-20 Reverse Stock Splitfinanznachrichten.de - November 10 at 5:52 PMAileron Therapeutics Announces a 1-for-20 Reverse Stock Splitfinance.yahoo.com - November 10 at 5:51 PMAileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgradefinance.yahoo.com - November 4 at 3:30 PMAileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlightstechnews.tmcnet.com - November 1 at 5:55 PMAileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlightsfinance.yahoo.com - November 1 at 5:55 PMAileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conferencefinance.yahoo.com - October 26 at 8:45 AMAileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022finance.yahoo.com - September 30 at 1:11 PMAileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conferencefinance.yahoo.com - September 22 at 11:20 AMAileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 11:48 AMAileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlightsfinance.yahoo.com - August 16 at 8:23 AM Get Aileron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). ALRN Media Mentions By Week ALRN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALRN News Sentiment▼-0.500.40▲Average Medical News Sentiment ALRN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALRN Articles This Week▼20▲ALRN Articles Average Week Get Aileron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: InflaRx News Oncolytics Biotech News Affimed News Leap Therapeutics News Marinus Pharmaceuticals News LifeVantage News Chimerix News Spero Therapeutics News Eton Pharmaceuticals News Connect Biopharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALRN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & CompanyThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
